ClinicalTrials.gg
RecruitingNCT07298447Updated Nov 2, 2026

Donidalorsen Treatment in Children With Hereditary Angioedema

A Phase 3 interventional study of Donidalorsen in Hereditary Angioedema (HAE), sponsored by Ionis Pharmaceuticals, Inc.. Recruiting at 18 sites in 5 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 2, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Planned enrollment
61st of 74
20 · median 57
Started
2026
with 2 others
Phase 3
38 of 84
6 open now
Primary completion
2029-06
later than 13 of 17 live
Registered
82nd of 84
by date
Lead sponsor
5 of 84
Ionis Pharmaceuticals, Inc.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 61st largest by planned enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 in phase 3, reaches primary completion later than 13 of the 17 other live ones, and was the 82nd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).

Read the detailed description

This is an open-label study to evaluate the safety, efficacy, and pharmacokinetics (PK) and pharmacodynamics (PD) of donidalorsen in pediatric participants age 2 to less than 12 years old with HAE Type I (HAE-1) or Type II (HAE-2). The study consists of 3 parts: 1) a 3-month Screening Period, 2) a one-year Treatment Period, and 3) a 3-month Post-Treatment Period.

03

Conditions studied

  • Hereditary Angioedema (HAE)
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Must be between the ages of 2 and less than 12 years, inclusive, at the time of and, as applicable, assent.
  2. Must weigh at least 9 kg at the time of informed consent and, as applicable, assent.
  3. Documented diagnosis of HAE-1/HAE-2 based upon both of the following:

    1. Documented clinical history consistent with HAE (SC or mucosal, non-pruritic swelling episodes without accompanying urticaria).
    2. Diagnostic testing results that confirm HAE-1/HAE-2: C1-inhibitor (C1-INH) functional level \<50% normal level AND complement factor C4 level below the lower limit of normal (LLN); OR a known pathogenic mutation in the SERPING1 gene.

Key Exclusion Criteria:

  1. Must not have any screening laboratory abnormalities or any other abnormalities during screening that would render a participant unsuitable for inclusion.
  2. Must not have been treated with another drug, biological agent, or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer.
  3. Concurrent diagnosis of any other type of recurrent angioedema, including idiopathic angioedema or HAE with normal C1-INH (HAE-nC1-INH or Type III).

Note: Other protocol-specified inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Donidalorsen: Group 1

    Participant weighing 9 kilograms (kg) to less than (\<)26 kg, will be administered donidalorsen over the period of one year.

    Drug: Donidalorsen

  • Experimental
    Donidalorsen: Group 2

    Participant weighing greater than or equal to (≥)26 kg to \<41 kg, will be administered donidalorsen over the period of one year.

    Drug: Donidalorsen

  • Experimental
    Donidalorsen: Group 3

    Participant weighing ≥41kg, will receive donidalorsen over the period of one year.

    Drug: Donidalorsen

Interventions

  • Donidalorsen will be administered by subcutaneous (SC) injection.

    Also known as: ISIS 721744, IONIS-PKK-LRx

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: over the period of approximately 17 months

  2. Maximum Plasma Concentration (Cmax) of Donidalorsen

    Time frame: over the period of approximately 17 months

  3. Maximum Time to Reach Cmax (Tmax) of Donidalorsen

    Time frame: over the period of approximately 17 months

  4. Trough Plasma Concentration (Ctrough) of Donidalorsen

    Time frame: over the period of approximately 17 months

Secondary outcomes

  1. Time-Normalized Number of Investigator-Confirmed HAE Attacks (per Month)

    Time frame: over the period of 12 months

  2. Percentage of Investigator-Confirmed HAE Attack-free Participants

    Time frame: over the period of 12 months

  3. Time-Normalized Number of Moderate or Severe Investigator-Confirmed HAE Attacks (per Month)

    Time frame: over the period of 12 months

  4. Number of Participants with a Clinical Response Defined as a ≥ 50 Percent (%), ≥ 70% and ≥ 90% Reduction from Baseline in Investigator-Confirmed HAE Attack Rate

    Time frame: over the period of 12 months

  5. Time-Normalized Number of Investigator-Confirmed HAE Attacks Requiring Rescue Treatment

    Time frame: over the period of 12 months

  6. Change From Baseline in Prekallikrein (PKK) Levels in Plasma

    Time frame: over the period of 12 months

  7. Percent Change From Baseline in PKK Levels in Plasma

    Time frame: over the period of 12 months

  8. Changes in Pediatrics Quality of Life (PedsQL) Scores for Participants

    Time frame: over the period of 12 months

07

Study locations

18 of 18 sites recruiting
  • Ionis Investigative Site
    Santa Monica, California 90404, United States
    Recruiting
  • Ionis Investigative Site
    Miami, Florida 33136, United States
    Recruiting
  • Ionis Investigative Site
    Baton Rouge, Louisiana 70809, United States
    Recruiting
  • Ionis Investigative Site
    St Louis, Missouri 63141, United States
    Recruiting
  • Ionis Investigative Site
    Cincinnati, Ohio 45236, United States
    Recruiting
  • Ionis Investigative Site
    Cleveland, Ohio 44195, United States
    Recruiting
  • Ionis Investigative Site
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • Ionis Investigative Site
    West Allis, Wisconsin 53214, United States
    Recruiting
  • Ionis Investigative Site
    South Brisbane, Queensland 4101, Australia
    Recruiting
  • Ionis Investigative Site
    Clayton, Victoria 3168, Australia
    Recruiting
  • Ionis Investigative Site
    Murdoch, 6150, Australia
    Recruiting
  • Ionis Investigative Site
    Milan, 20157, Italy
    Recruiting
  • Ionis Investigative Site
    Padova, 35128, Italy
    Recruiting
  • Ionis Investigative Site
    Roma, 00133, Italy
    Recruiting
  • Ionis Investigative Site
    San Donato Milanese, 20097, Italy
    Recruiting
  • Ionis Investigative Site
    Krakow, 31-501, Poland
    Recruiting
  • Ionis Investigative Site
    Warsaw, 04-501, Poland
    Recruiting
  • Ionis Investigative Site
    Barcelona, 08035, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2029, 38 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's planned 38 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Dec 23, 2025
StartActual
Apr 21, 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 Australia, 1 Poland)
  • Ionis Investigative Site · Murdoch, Australia
  • Ionis Investigative Site · Krakow, Poland
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    2 sites added
    Show 2 added (1 Australia, 1 Poland)
    • Ionis Investigative Site · Murdoch, Australia
    • Ionis Investigative Site · Krakow, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07298447
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Apr 21, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Ionis Pharmaceuticals, Inc.
Contact
IonisDonidalorsenPediatric@clinicaltrialmedia.com
(844) 201-3192

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donidalorsen

Start the discussion